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and KIR Haplotype B Donors after Nonmyeloablative,
HLA-Haploidentical Bone Marrow Transplantation
Heather J. Symons,1 M. Sue Leffell,2 Nancy D. Rossiter,2 Marianna Zahurak,1
Richard J. Jones,1 Ephraim J. Fuchs1Natural killer (NK) cell alloreactivity, which may contribute to the graft-versus-leukemia (GVL) effect of al-
logeneic hematopoietic stem cell transplantation (HSCT), is influenced by the interaction of killer-cell immu-
noglobulin-like receptors (KIRs) on donor NK cells and their ligands, human leukocyte antigen (HLA) class I
molecules on recipient antigen-presenting cells (APCs). Distinct models to predict NK cell alloreactivity dif-
fer in their incorporation of information from typing of recipient and donor KIR and HLA gene loci, which
exist on different autosomes and are inherited independently as haplotypes. Individuals may differ in the in-
heritance of the 2 KIR haplotypes, A and B, or in the expression of individual KIR genes. Here, we examined
the effect of KIR and HLA genotype, in both the recipient and donor, on the outcome of 86 patients with
advanced hematologic malignancies who received nonmyeloablative (NMA), HLA-haploidentical HSCT
with high-dose, posttransplantation cyclophosphamide (Cy). Compared to recipients of bone marrow
(BM) from donors with identical KIR gene content, recipients of inhibitory KIR (iKIR) gene-mismatched
BM had an improved overall survival (OS) (hazard ratio [HR]5 0.37; confidence interval [CI]: 0.21-0.63;
P5.0003), event-free survival (EFS) (HR5 0.51; CI: 0.31-0.84; P5.01), and relapse rate (cause-specific
HR, SDHR5 0.53; CI: 0.31-0.93; P5.025). Patients homozygous for the KIR ‘‘A’’ haplotype, which encodes
only 1 activating KIR, had an improved OS (HR5 0.30; CI: 0.13-10.69; P5.004), EFS (HR5 0.47; CI: 0.22-
1.00; P5.05), and nonrelapse mortality (NRM; cause-specific HR5 0.13; CI: 0.017-0.968; P5.046) if their
donor expressed at least 1 KIR B haplotype that encodes several activating KIRs. Models that incorporated
information from recipient HLA typing, with or without donor HLA typing, were not predictive of outcome
in this patient cohort. Thus, NMA conditioning and T cell-replete, HLA-haploidentical HSCTs involving iKIR
gene mismatches between donor and recipient, or KIR haplotype AA recipients of BM from KIR Bx donors,
were associated with lower relapse andNRM and improvedOS and EFS. These findings suggest that selection
of donors based upon inhibitory KIR gene or haplotype incompatibility may be warranted.
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Alloreactive natural killer (NK) cells have been
shown to play a significant role in the outcomes of
patients with hematologic malignancies after hemato-
poietic stem cell transplantation (HSCT). The molec-
ular basis of NK cell alloreactivity is not completely
understood, but it is known to involve a dynamic bal-
ance of signals mediated through activating as well as
inhibitory receptors on the NK cell. Killer cell immu-
noglobulin-like receptors (KIRs), consisting of inhibi-
tory and activating groups, are expressed on NK cells
as well as on a subset of T cells. Some of the inhibitory
KIRs (KIRs), recognize specific HLA class I ligands533
Figure 1. Models of natural killer cell alloreactivity after allogeneic cell transplantation. (A) TheKIR ligand incompatibility, or ligand-ligandmodel predicts
NKcell alloreactivity in theGVHdirection (depicted by jagged arrow)when the recipient lacks expressionof an inhibitoryKIR ligand, in this case amember
of the HLA-C1 group, that is present in the donor. This model assumes the presence of functional donor NK cells expressing KIR2DL2, the receptor for
HLA-C1 molecules, as their inhibitory receptor. (B) The receptor-ligand model predicts NK cell alloreactivity in the GVH direction when the recipient
lacks the expression of an HLA ligand for a verified donor inhibitory KIR. The HLA type of donor cells is not considered in this model. (C) The missing
ligandmodel predictsNK cell alloreactivity in theGVHdirectionwhen recipient cells lacks expression of at least 1 of theHLA ligands (C1, C2, or Bw4) for
averified donor inhibitoryKIR.As in B, theHLA typeof the donor is not considered in thismodel. (D) TheKIR gene-genemodel predictsNKalloreactivity
when the donor and recipient are mismatched for KIR gene content. This model characterizes the KIR genotype of both donor and recipient, and asks
whether differences in the expression of individual inhibitory or stimulatory genes between the donor and the recipient KIR (ie, donor includes inhibitory
KIR genes that the recipient is missing or vice versa) have any effect on the outcome of allogeneic SCT. Inhibitory KIR genes are shown here as unshaded
boxes, whereas black boxes represent activating KIR genes. In the example shown, the donor has several activating and inhibitory genes that the recipient
lacks. This example also illustrates the KIR haplotype characterization. In this case, the donor is haplotype group B, based on the presence of several ac-
tivating KIR genes, whereas the recipient is haplotype group A based on the presence of inhibitory genes and only 1 activating gene.
534 Biol Blood Marrow Transplant 16:533-542, 2010H. J. Symons et al.including the well-defined specificity of KIR2DL2/3
for the HLA-Cw group-1 epitope, the specificity of
2DL1 for the Cw group-2 epitope, and the specificity
of 3DL1 for the HLA Bw4 epitope [1].
KIR genes segregate independently of HLA
genes, such that matching for HLA does not match
for KIRs. The KIR genes are clustered together on
chromosome 19q13.2 and, like the HLA genes, are
inherited together as a haplotype [2]. Two distinct
haplotypes exist, groups A and B, varying in the
type and number of genes present. The KIR group
A haplotype is uniform in terms of gene content
(3DL3, 2DL3, 2DL1, 2DP1, 3DP1, 2DL4, 3DL1,
2DS4, and 3DL2), of which all but 1 encode inhibi-
tory receptors. In contrast, the KIR group B haplo-
type is more diverse in the KIR genes it contains,
has more activating receptors, and is characterized
by the 2DL2, 2DS1, 2DS2, 2DS3, and 2DS5 genes
[2]. Individual KIR genes are highly polymorphic
[3], second in polymorphism only to the HLA genes.
The functional significance of KIR gene polymor-
phism is not yet known, and most studies of thecontribution of KIR genes to NK cell alloreactivity
do not distinguish individual KIR gene alleles.
In the setting of allogeneic HSCT, donor NK cells
may attack recipient cells that lack the appropriate
HLA class I ligands for the donor iKIR. After alloge-
neic HSCT, NK cells are the first lymphocyte subset
to reconstitute peripheral blood (PB) [4-6]. Although
some studies have demonstrated a beneficial effect of
NK cell alloreactivity on HSCT outcomes [5,7-10],
others have shown inferior rates of relapse and graft-
versus-host disease (GVHD) [11,12], and still others
have reported that NK cell alloreactivity has no effect
on HSCT outcomes [10,13]. Reasons for these con-
flicting results include the heterogeneity in HSCT
protocols employed, namely, differences in inclusion
criteria, the HSCT preparative regimen and graft
content, the degree of donor HLA-incompatibility,
and posttransplant immunosuppression. At least 4
models of NK cell alloreactivity (Figure 1) have been
proposed to predict HSCT outcomes: (1) KIR ligand
incompatibility, or ligand-ligand model [7,11,14-16]
(Figure 1A); (2) receptor-ligand model [9] (Figure 1B);
Figure 2. Nonmyeloablative haploidentical BMT conditioning and
postgrafting immunosuppresive regimen.
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gene-gene model [10,13] (Figure 1D). Contradictory
results obtained from these models have made it diffi-
cult to conclude which model is most predictive of
transplant outcome.
To evaluate the impact of KIR mismatches on
HSCT outcome measures, we performed a retrospec-
tive study of 86 patients with high-risk hematologic
malignancies who had been transplanted between
1999 and 2007 with T-replete bone marrow (BM)
from haploidentical donors after nonmyeloablative
(NMA) conditioning with a novel posttransplantation
immunosuppressive regimen including posttransplan-
tation cyclophosphamide (Cy). Using 3 of the 4models
(ligand incompatibility, missing-ligand, and gene-gene
models), we determined that donor-recipient inhibi-
tory KIR gene-gene mismatches as well as KIR haplo-
type group A recipients of B donors have improved
clinical outcomes. Because most patients have multiple
potential haploidentical donors, this might allow opti-
mal donor selection to improve BM transplantation
(BMT) outcome.PATIENTS AND METHODS
Patients
The study population consisted of 86 consecutive
patients who were enrolled in 1 of 2 similar clinical tri-
als, J9966 (Phase I) and J0457 (Phase II), at Johns Hop-
kins between 1999 and 2007. The primary outcomes of
40 of these patients have been reported previously [17].
Utilizing the models of NK cell alloreactivity, the out-
comes of these 40 patients and an additional 46 consec-
utively enrolled patients have been included here.
Eligible patients were 0.5 to 70 years of age, with
high-risk hematologic malignancies as previously
described [17] for whom standard allogeneic (HLA-
matched, related or unrelated) or autologous BMT
was unavailable or inappropriate. The protocols were
approved by the institutional review boards of the Johns
Hopkins Medical Institutions. All patients signed con-
sent forms approved by the institutional review board.
HLA and KIR Typing
HLA typing prior to allogeneic BMT (BMT) was
performed as previously reported [17]. The presenceor absence of KIR genes was determined using PCR se-
quence-specific amplification from genomic DNA ex-
tracts prepared by an automated procedure using the
GENOM-4 (Genovision Cytomics, Exton, PA).
KIR genes/allele groups were amplified using specific
primer sets (Pel-Freez, Dynal Biotech, Oslo, Norway)
for the KIR genes recognized by the International No-
menclature Committee of the World Health Organi-
zation [1]. The KIR amplicons were visualized with
ethidium bromide after agarose gel electropheresis.
Potential KIR alloreactivity was assessed by 3 of
the 4 models described previously: ligand incompati-
bility, missing ligand, and gene-gene models. High-
resolution HLA typing was used to assign donor and
recipient alleles of HLA-B and HLA-C to iKIR ligand
groups [14,18] and to determine donor/recipient iKIR
ligand compatibility. An iKIR gene-gene mismatch
was defined as an iKIR gene that was present in the do-
nor but absent in the recipient, or vice versa. The KIR
haplotype model was used to categorize all donors and
recipients as having 1 of 2 KIR genotypes: AA, which is
homozygous for group AKIR haplotypes, or Bx, which
contains either 1 (AB) or 2 (BB) group B haplotypes.
The inheritance of at least 1 B haplotype was deter-
mined by the expression of specific activating KIR
genes and 1 inhibitory KIR, as determined by the
gene-gene model, which are not components of the
group A haplotypes.
Conditioning Regimen and Postgrafting
Immunosuppression (Figure 2)
Patients on the 2 protocols were treated according
to the previously published regimens [17] described in
Figure 2, which differed in terms of postgrafting im-
munosuppression. Patients treated on J9966 received
either 1 dose of posttransplantation Cy and twice daily
mycophenolate mofetil (MMF; Cellcept, Roche Lab-
oratories, Nutley, NJ) (Hopkins A; n5 20) or 2 doses
of posttransplantation Cy (Hopkins B; n5 40) and
thrice daily MMF. Patients on J0457 received 2 doses
of posttransplantation Cy and thrice daily MMF
(n5 26). All patients were intended to be treated as
outpatients. Pharmacologic prophylaxis of GVHD
was initiated on the day following completion of post-
transplantation Cy. Acute GVHD (aGVHD) was
graded according to the Keystone Criteria [19].
First-line therapy for clinically significant aGVHD
consisted of methylprednisolone 1-2.5 mg/kg/day i.v.
plus full-dose tacrolimus or full-dose tacrolimus plus
resumption of MMF.
Statistical Methods
Patient outcomes were updated most recently on
December 8, 2008. A description of protocol specific
phase I and II parameters for J9966 Hopkins A and
B, and for J0457, has been previously published [17].
Table 1. Patient Characteristics
No. Patients 86
Median age, year (range) 48 (1-71)
Sex, n (%)
Male 52 (60)
Female 34 (40)
Ethnicity, n (%)
Caucasian 70 (82)
African American 14 (16)
Asian 2 (2)
Diagnosis, n (%)
AML 25 (30)
ALL 7 (8)
MDS 8 (9)
CML/CMML 11 (13)
CLL 8 (9)
HL 7 (8)
NHL 14 (16)
MM/plasmacytoma 6 (7)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous
leukemia; CMML, chronic myelomonocytic leukemia; CLL, chronic lym-
phocytic leukemia; HL, Hodgkin lymphoma; NHL, non-Hodgkin lym-
phoma; MM, multiple myeloma.
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survival (EFS) were estimated using the Kaplan-Meier
method [20] and compared using the log-rank statistic
[21] or the Cox proportional hazards regression model
[22]. Stratified Cox regressionmodels were used to ob-
tain KIR mismatch multivariate estimates specific for
lymphoid and myeloid disease types by including stra-
tum-covariate interaction effects. Probabilities of
aGVHD and chronic GVHD (cGVHD), relapse,
and nonrelapsemortality (NRM)were summarized us-
ing cumulative incidence estimates [23]. Death with-
out engraftment was considered a competing risk for
engraftment, death without relapse was a competing
risk for relapse, relapse was a competing risk for
NRM, and graft failure, relapse, or death without
GVHD was considered competing risks for GVHD.
The hazard of failure for each of these endpoints was
compared using proportional subdistribution hazard
regression models for competing risks endpoints
[24,25]. All P-values are 2-sided and all confidence in-
tervals (CIs) are 95% CIs. Computations were per-
formed using the Statistical Analysis System, or R.Table 2. Donor and Graft Characteristics (n5 86)
Median age, years (range) 44 (21-69)
Sex, n (%)
Male 40 (47)
Female 46 (53)
Relationship, n (%)
Parent 23 (27)
Sibling 43 (50)
Child 20 (23)
CD3+ cells/kg 1027
Mean (SD) 3.8 (1.3)
CD34+ cells/kg 1026
Mean (SD) 4.3 (1.7)
Infused MNC/kg 1028
Mean (SD) 1.5 (0.9)
HLA Mismatches,* n (%) HVG Direction GVH Direction
0 1 (1) 1 (1)
1 3 (4) 4 (5)
2 8 (10) 8 (10)
3 22 (28) 24 (31)
4 31 (40) 34 (44)
5 13 (17) 7 (9)
Median (range) 4 (0-5) 4 (0-5)
MNC indicates mononuclear cell count; HVG, host-versus-
graft; GVH, graft-versus-host; SD, standard deviation.
*n5 82.RESULTS
Patient and Graft Characteristics
Characteristics of the 86 patients enrolled in the
studies are listed in Table 1. All study subjects had
poor-risk hematologic malignancies, as previously
defined [17]. Eighteen percent of the patients were
from ethnic minority groups.
Characteristics of the donors and grafts are listed in
Table 2. The number of HLA allele mismatches in the
host-versus-graft (HVG) or graft-versus-host (GVH)
directions are listed. Donors differed from their recip-
ients at a median of 4 HLA loci in both the HVG and
GVH directions. More than 50% of donor-recipient
pairs were mismatched for at least 4 HLA loci.
KIR Mismatches
The ligand incompatibility model predicted the
lowest frequency of NK alloreactive donors (26/86,
30%), only about half as many as predicted by the
other methods: missing ligand model (57/84, 68%)
and the gene-gene model for inhibitory KIR (49/85,
58%). Of 85 evaluable patients, 30 had KIR haplotype
mismatches (AA donor into Bx recipient, 10/85 [12%],
and Bx donor into AA recipient, 20/85 [24%]); the
remaining 55 recipient-donor pairs (65%) were haplo-
type-compatible (AA donor into AA recipient, 15/85
[18%], and Bx donor into Bx recipient, 40/85 [47%]).
aGVHD, NRM, Relapse, OS, and EFS
The probabilities of grades II-IV and III-IV
aGVHD by day 100 were 33% and 8%, and by day200 were 35% and 12%, respectively (Figure 3A).
The cumulative incidences of NRM at 100 days and
at 1 year after transplantation were 9% and 21%,
respectively (Figure 3B), and the probabilities of re-
lapse at 1 and 2 years after transplantation were 50%
and 58%, respectively (Figure 3C). There was no dif-
ference in relapse rate between those patients with
lymphoid and myeloid malignancies (cause-specific
hazard ratio [HR]5 1.03; CI: 0.59-1.8; P5 .91).
At a median follow-up among survivors of 916 days
(range: 112-1808 days), the actuarial OS at 1 and at 2
years after transplantation were 46% and 34%, respec-
tively (Figure 3D). The actuarial EFS at 1 and at 2
years were 30% and 23%, respectively (Figure 3E).
In univariate analysis, OS and EFS were significantly
Figure 3. Overall outcomes among nonmyeloablative haploidentical BMT recipients. Cumulative incidence of (A) aGVHD, grades II-IV and III-IV, (B)
NRM and (C), Relapse. (D) OS, and (E) EFS.
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matched in the GVH direction (4-5 mismatches versus
1-3 mismatches, HR5 0.5; CI: 0.29-0.86; P5 .01 and
HR 0.5; CI: 0.3-0.84; P5 .01). There was no statisti-
cally significant difference in any outcome between
the groups of patients who received 1 versus 2 doses
of posttransplantation Cy (data not shown).
Inhibitory KIR Gene Mismatches
Donor/recipient pairs who differed in iKIR gene
content had significantly improved OS (HR5 0.37;
CI: 0.21-0.63; P5 .0003) and EFS (HR5 0.51; CI:
0.31-0.84; p5 .01) (Figure 4A and B) when compared
to those patient-donor pairs with identical iKIR gene
content. The OS benefit of iKIR gene mismatches
was found in patients with lymphoid diseases
(HR5 0.44; CI: 0.20-0.93; P5 .03) as well as in
patients with myeloid diseases (HR5 0.32; CI:
0.15-0.69, P5 .004). Furthermore, patient-donor
pairs with inhibitory KIR genemismatches had a lower
rate of relapse than those without mismatches (cause-
specific HR5 0.53; CI: 0.31-0.93; P5 .025)(Figure 4C). There was no significant difference in
NRM between those patient-donor pairs with inhibi-
tory KIR mismatches compared to those without
(cause-specific HR5 0.95; CI: 0.36-2.52; P5 .92).
To explore further the influence of inhibitory KIR
mismatches on OS and EFS, a multivariate analysis
was performed with disease type (myeloid versus lym-
phoid), number of HLA mismatches in the GVH and
HVG direction, graft CD3 count, cytomegalovirus
(CMV) status, and 1 versus 2 doses of posttransplant
Cy as candidate predictors. In the final model, adjust-
ing for HLA allele mismatches, the benefit of in-
hibitory KIR gene mismatching on OS and EFS
remained significant (HR 0.4; CI: 0.23-0.71;
P5 .002 and HR 0.51; CI: 0.3-0.87; P5 .01, respec-
tively) (Table 3A andD).When performing amultivar-
iate analysis for OS and EFS stratified by disease type
(myeloid versus lymphoid), patients with lymphoid
disease and inhibitory KIR mismatches had an im-
proved OS (Table 3B; HR 0.41; CI: 0.18-0.93;
P5 .03) with a trend toward an improved EFS (Table
3E; HR 0.54; CI: 0.25-1.16; P5 .11), whereas those
Figure 4. Gene-gene inhibitory KIR mismatches and OS, EFS and relapse. (A) OS. (B) EFS. (C) Cumulative incidence of relapse.
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matches had an improved OS and EFS (HR 0.34; CI:
0.15-0.77; P5 .01 and HR5 0.47; CI: 0.22-0.98;
P5 .05) (Table 3B and E). There were no significant
differences in aGVHD or cGVHD, NRM, or engraft-
ment failure between patient-donor pairs with or with-
out inhibitory KIR genotype mismatches (data not
shown).Haplotype Mismatches
Patients and donors were classified as either having
haplotype AA or Bx, as described in the Methods sec-
tion. Because the recipient’s KIR haplotypes are fixed,
but donors can be selected based upon KIR haplotype,
we analyzed the effect of donor KIR haplotype on the
outcome of SCT. Patients with the AA haplotype had
a significantly improved OS (HR5 0.30; CI:
0.13-0.71; P5 .01) and EFS (HR5 0.47; CI: 0.22-
1.00; P5 .05) if their donor had a Bx haplotype (mis-
matched) rather than an AA haplotype (matched)
(Figure 5A and B). AA recipients of BM from Bx do-
nors also had a lower NRM (HR5 0.13; CI: 0.017-
0.968; P5 .046) (Figure 5C). No effect was seen on
relapse rate (HR 1.05, CI: 0.44-2.51; P5 .91). To
explore further the influence of donor KIR haplotypes,
a multivariate analysis was constructed adjusted for
significant clinical and demographic factors including
age, disease status, and number of HLA allele mis-
matches in the GVH direction. After adjustment, the
benefit of transplantation on OS using haplotype B
donors for haplotype A recipients remained signifi-
cant (Table 3C; HR 0.35; CI: 0.14-0.85; P5 .02) andmarginally significant for EFS (Table 3F; HR 0.49;
CI: 0.21-1.14; P5 .1).
For patients with haplotype Bx, there was no dif-
ference in OS or EFS based on donor haplotype
(HR5 0.69; CI: 0.27-1.78; p5 .44 and HR5 1.28;
CI: 0.58-2.80, p5 0.54, respectively) (Figure 6A and B).
Therewere no significant differences in relapse, engraft-
ment failure, aGVHD, or cGVHD based on
donor-recipient haplotype combinations (data not
shown).Other Models
When we utilized the other proposed models
(ligand-incompatibility, missing ligand, and gene-
gene for stimulatory KIR), we saw no significant differ-
ences in any patient outcomes (data not shown).
Patient-donor pairs with stimulatory KIR gene mis-
matches did show a trend toward an improved OS
(HR5 0.59; CI: 0.34-1.00; P5 .05), and those with
receptor-ligand mismatches did show a trend toward
a significant increase in aGVHD (cause specific
HR5 2.18; CI: 0.914-5.20; P5 .08).DISCUSSION
In this NMA haploidentical HSCT study utilizing
T cell-replete grafts and a novel posttransplantation
immunosuppressive regimen including Cy for high-
risk, poor-prognosis hematologic malignancy patients,
we found that regardless of disease type, patient-donor
pairs with inhibitory KIR gene mismatches had im-
proved OS, EFS, and a lower rate of relapse.
Table 3. Overall and Event-Free Survival: Multivariate Anal-
ysis
A. Overall Survival and Inhibitory KIR Gene Mismatches
HR 95% CI P
Inhibitory KIR gene mismatches 0.4 0.23-0.71 .002
$4 HLA allele mismatches (GVH) 0.58 0.34-1.02 .06
B. Overall Survival and Inhibitory KIR Gene
Mismatches Stratified by Disease Yype
HR 95% CI P
Inhibitory KIR gene mismatches (lymphoid) 0.41 0.18-0.93 .03
Inhibitory KIR gene mismatches (myeloid) 0.34 0.15-0.77 .01
$4 HLA allele mismatches (GVH) 0.53 0.3-0.94 .03
Age >50 1.56 0.88-2.77 .13
C. Overall Survival and Haplotype
HR 95% CI P
Bx donor to AA recipient 0.35 0.14-0.85 .02
$4 HLA allele mismatches (GVH) 0.53 0.3-0.93 .03
Age >50 1.45 0.83-2.55 .19
Lymphoid malignancy 1.11 0.64-1.94 .71
AA donor to Bx recipient 0.36 0.12-1.03 .06
Bx donor to Bx recipient 0.53 0.27-1.06 .07
D. Event-Free Survival and Inhibitory KIR Gene Mismatches
HR 95% CI P
Inhibitory KIR gene mismatches 0.51 0.3-0.87 .01
$4 HLA allele mismatches (GVH) 0.57 0.33-0.96 .03
E. Event-Free Survival and Inhibitory KIR
Gene Mismatches Stratified by Disease Type
HR 95% CI P
Inhibitory KIR gene mismatches (lymphoid) 0.54 0.25-1.16 .11
Inhibitory KIR gene mismatches (myeloid) 0.47 0.22-0.98 .05
$4 HLA allele mismatches (GVH) 0.52 0.3-0.89 .02
Age >50 1.48 0.86-2.53 .15
F. Event-Free Survival and Haplotype
HR 95% CI P
Bx donor to AA recipient 0.49 0.21-1.14 .1
$4 HLA allele mismatches (GVH) 0.54 0.31-0.93 .03
Age >50 1.47 0.86-2.51 .16
Lymphoid malignancy 1.06 0.63-1.79 .82
AA donor to Bx recipient 0.8 0.32-2.03 .64
Bx donor to Bx recipient 0.71 0.36-1.38 .31
HR indicates hazard ratio; CI, confidence interval; GVH, graft-versus-
host; KIR, killer immunoglobulin receptor.
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plant recipients of KIR genotype Bx donors (Bx/
AA) had an improved OS, EFS, and significantly lower
NRM. Because most patients have multiple potential
haploidentical donors, this might allow for optimal do-
nor selection to improve outcomes after T cell-replete
haploidentical BMT.
These results are particularly noteworthy because
our regimen included T cell-replete grafts. T cell de-pletion is thought to facilitate NK cell recovery and
perhaps NK alloreactivity [26], and the majority of
work identifying a benefit of NK cell alloreactivity in
the haploidentical setting has been done with T cell-
depleted grafts [11,14,27-29]. Furthermore, the bene-
fit of NK alloreactivity has been demonstrated
predominantly after HSCTs that have not included
posttransplantation immunosuppressive agents, unlike
our novel regimen, which includes posttransplantation
Cy,MMF, and tacrolimus. It is possible that posttrans-
plantation Cy eliminates the recently activated T cells
responsible for interfering with effective NK cell re-
constitution and alloreactivity. It is also possible that
the benefit of KIR mismatches in prior studies using
T cell replete grafts was outweighed by higher rates
of GVHD and thus higher rates of NRM, and that
the elimination of host-reactive T cells by posttrans-
plantation Cy unmasks the benefit of KIR genotype
and haplotype mismatches. Further laboratory studies
to look at the mechanism of Cy-induced T cell toler-
ance and characterize NK cell reconstitution after
this transplant regimen are ongoing.
A benefit of iKIR gene mismatching, as is seen
most clearly in Figure 4, implies that donor NK
cell alloreactivity depends upon the iKIR gene reper-
toire of the recipient. We can envision 2 possibilities
for how recipient iKIR genes, via the NK or T cells
that express them, can influence donor NK and/or
T cell alloreactivity. First, allelically variable peptide
sequences from recipient iKIR molecules may be pre-
sented by recipient HLA Class I molecules, thereby
acting as minor histocompatibility antigens to stimu-
late a graft-versus-tumor response from donor T
cells. A second possibility is that, prior to transplan-
tation, the relative expression of HLA Class I alleles
on tumor cells is selected by recipient NK cells and
their iKIRs to levels that permit the tumor to escape re-
cipient NK cell cytotoxicity. However, this level of
HLAClass Imolecule expression, which has effectively
been ‘‘imprinted’’ by recipient NK cells, may not be
optimally tuned to avoid donorNKcell killing, thereby
leading to an enhancedNKcell-mediated graft-versus-
tumor effect.
Previous studies have examined the effect of donor
and recipient KIR genotypes on the outcome of alloge-
neic HSCT [13,30,31]. One study found a 100% risk
of GVHD after unrelated donor BMT, when the do-
nor contained KIR genes absent in the recipient,
compared to a 60% risk of GVHD with other combi-
nations [13]. Another study has shown significantly
higher rates of graft rejection in KIR genotype identi-
cal versus mismatched BMTs [32]. The presence of
specific KIR genes has also been shown to influence
the prognosis of or modulate certain autoimmune
and infectious diseases [33-37].
Previous studies have also shown a benefit of trans-
plants from Bx donors [38,39]. In the setting of T
Figure 5. OS, EFS, and NRM for haplotype A recipients of B donors. (A) OS. (B) EFS. (C) Cumulative incidence of NRM.
540 Biol Blood Marrow Transplant 16:533-542, 2010H. J. Symons et al.cell-replete, HLA-matched sibling BMT involving
CMV-positive recipients and their CMV-positive do-
nors, recipients of haplotype B donors had only a 24%
rate of CMV reactivation, whereas recipients of haplo-
type A donors had a 71% rate of CMV reactivation
[40]. These results had not previously been shown
with HLA-haploidentical donor BMT involving T
cell depletion, suggesting that the protective effect of
donor CMV-specific cells might depend upon the
KIR genotype/haplotype of the donor and the pres-
ence of donor lymphocytes at the time of transplanta-
tion. In another study, acute myelogenous leukemia
(AML) recipients of grafts from KIR haplotype B do-
nors had a significantly improved EFS secondary to
a markedly reduced NRM after T cell-depleted,Figure 6. OS and EFS for haplotype B recHLA-haploidentical HSCT [41]. In agreement with
Cooley et al. [39], despite the benefit of haplotype Bx
donors for A recipients, we did not observe a benefit
from increased numbers of activating KIR genes or
the presence of KIR2DS2 in the donor. Likewise, we
did not find any significant effect on outcome from
the presence of KIR2DS1 and 2DS2 in the donor, or
donors, with more than 4 activating KIRs as has been
previously shown [30,39,42].
In contrast to our study, detrimental effects of ac-
tivating or haplotype B donors have also been reported
[31,43]. In HLA-matched related BMTs, the presence
of activating KIR, or haplotype B donors, has been
correlated with increased rates of aGVHD [31] and
relapse [43] in patients with myeloid malignancies.ipients of A donors. (A) OS. (B) EFS.
Biol Blood Marrow Transplant 16:533-542, 2010 541KIR Genes and Outcome of HLA-Haploidentical BMTAlthough the underlying mechanisms are still
unclear, our results suggest that donor/recipient
mismatches of inhibitory KIR genes or specific KIR
gene haplotypes are associated with improved OS and
EFS after T cell-replete, HLA-haploidentical BMT
with posttransplantation Cy for hematologic malig-
nancies. We are currently investigating whether donor
and recipient KIR genes influence the outcome of T
cell-replete, HLA-haploidentical SCT with posttrans-
plantation Cy after myeloablative (MA) conditioning.
Because KIR genotyping is simple, dependable, and
relatively inexpensive, the prospective selection of
KIR mismatched donors to improve HSCT outcomes
remains a promising and feasible goal.ACKNOWLEDGMENTS
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